Skip to main content
TipRanks
Go Ultimate75% OFF

Revolution Medicines (42Z) Stock Forecast & Price Target

17 Followers
See the Price Targets and Ratings of:

42Z Analyst Ratings

Strong Buy
24Ratings
23Buy1Hold0Sell
Based on 24 analysts giving stock ratings to Revolution Medicines in the past 3 months

42Z Stock 12 Month Forecast

€245.62▲(67.94% Upside)
Based on 24 Wall Street analysts offering 12 month price targets for Revolution Medicines in the last 3 months. The average price target is EUR 245.62 with a high forecast of EUR 318.34 and a low forecast of EUR 162.81. The average price target represents a 67.94% change from the last price of EUR 146.25.
Highest Price Target€318.34Average Price Target€245.62Lowest Price Target€162.81

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:42Z
Price TargetArticle
H.C. Wainwright€318.34buy117.67%UpsideReiterated11/17/26
Morgan Stanley€247.40→€224.66buy53.61%UpsideReiterated11/13/26
Bank of America Securities€249.22buy70.40%UpsideReiterated11/12/26
Stifel Nicolaus€209.20buy43.04%UpsideReiterated11/09/26
J.P. Morgan€223.75→€262.86buy79.73%UpsideReiterated11/09/26
Piper Sandler€191.01→€201.92buy38.06%UpsideReiterated11/05/26
RBC Capital€236.48→€291.97buy99.63%UpsideAssigned11/05/26
Wedbush€204.65buy39.93%UpsideReiterated11/05/26
Oppenheimer€236.48buy61.70%UpsideReiterated11/05/26
Evercore ISI€291.06→€309.25buy111.45%UpsideReiterated11/05/26
TD Cowen€227.39→€245.58buy67.92%UpsideAssigned11/05/26
Leerink Partners Analyst forecast on DE:42ZUnknown AnalystNot RankedLeerink Partners€261.95→€282.87buy93.42%UpsideReiterated11/05/26
Bernstein€162.81hold11.32%UpsideReiterated11/04/26
Guggenheim€250.13→€271.05buy85.33%UpsideReiterated11/04/26
UBS€241.03buy64.81%UpsideAssigned10/22/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
OVIDOvid Therapeutics
PTGXProtagonist Therapeutics
IMUXImmunic
IVAInventiva
PALIPalisade Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Revolution Medicines

3 Months
Charles Zhu
Charles ZhuLifeSci Capital
Success Rate10/14 ratings generated profit
71%
Average Return
+38.64%

Copying Charles Zhu's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +38.64% per trade.

1 Year
Michael Schmidt
Michael SchmidtGuggenheim
Success Rate16/20 ratings generated profit
80%
Average Return
+79.86%

Copying Michael Schmidt's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +79.86% per trade.

2 Years
Ami Fadia
Ami FadiaNeedham
Success Rate26/28 ratings generated profit
93%
Average Return
+180.63%

Copying Ami Fadia's trades and holding each position for 2 Years would result in 92.86% of your transactions generating a profit, with an average return of +180.63% per trade.

42Z Analyst Recommendation Trends

050100150200Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for 42Z
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy635613
Buy5074596437
Hold34443
Sell00000
Strong Sell00000
total5981687453

In the current month, 42Z has received 50 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 42Z average Analyst price target in the past 3 months is 245.62.

42Z Financial Forecast

€-4€-2.75€-1.5€-0.25€1Q1 2026Q3 2026Q4 2026
High€0.00
Consensus€-1.06
Low€-2.22

42Z Earnings Forecast

Next quarter’s earnings estimate for 42Z is -EUR 1.06 with a range of -EUR 2.22 to EUR 0.00. The previous quarter’s EPS was -EUR 1.73. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

€-1€144.4M€288.8M€433.2M€577.6MQ1 2026Q3 2026Q4 2026
High€578M
Consensus€367M
Low€163M

42Z Sales Forecast

Next quarter’s sales forecast for 42Z is EUR 367.41M with a range of EUR 163.36M to EUR 577.56M. The previous quarter’s sales results were EUR 179.69M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

42Z Stock Forecast FAQ

What is DE:42Z’s average 12-month price target, according to analysts?
Based on analyst ratings, Revolution Medicines’s 12-month average price target is €245.62.
What is DE:42Z’s upside potential, based on the analysts’ average price target?
Revolution Medicines has 67.94% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Revolution Medicines a Buy, Sell or Hold?
Revolution Medicines has a consensus rating of Strong Buy, which is based on 23 buy ratings, 1 hold ratings and 0 sell ratings.
What is Revolution Medicines’s share price target?
The average share price target for Revolution Medicines is €245.62. This is based on 24 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €318.34, and the lowest forecast is €162.81. The average share price target represents a 67.94% increase from the current price of €146.25.
What do analysts say about Revolution Medicines?
Revolution Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Street analysts.
How can I buy shares of Revolution Medicines?
To buy shares of DE:42Z, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.